about
MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic ConsiderationsDirect and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney TransplantationFlow cytometry and solid organ transplantation: a perfect matchGlobal scientific vision with local vigilance: renal transplantation in developing countriesDetailed polymorphism study on cytomegalovirus DNA polymerase gene to reveal the most suitable genomic targets for quantitative Real-time PCRThe host ubiquitin-dependent segregase VCP/p97 is required for the onset of human cytomegalovirus replication.Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant RecipientsVascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deteriorationTreatment of norovirus infections: moving antivirals from the bench to the bedside.Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.Ganciclovir use evaluation in kidney transplantation departments.Cytomegalovirus infections in solid organ transplantation: a review.Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.Opportunistic viral infections in intestinal transplantation.Cytomegalovirus vaccine: phase II clinical trial results.Treatment of cytomegalovirus infections beyond acute disease to improve human health.Tissue-resident T cells, in situ immunity and transplantation.Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation.Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients.Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections.Avoiding immunological rejection in regenerative medicine.Overcoming drug resistance in HSV, CMV, HBV and HCV infection.Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation.Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.Cytomegalovirus-Responsive CD8+ T Cells Expand After Solid Organ Transplantation in the Absence of CMV Disease.Cytomegalovirus infection in patients with lupus nephritis: clinical and laboratory features and therapeutic considerations.Drug Susceptibility and Replicative Capacity of Multi-Drug Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes.Evaluation of a Probe-Based PCR-ELISA System for Simultaneous Semi Quantitative Detection and Genotyping of Human Cytomegalovirus (HCMV) Infection in Clinical Specimens.Cytomegalovirus-Associated CD4(+) CD28(null) Cells in NKG2D-Dependent Glomerular Endothelial Injury and Kidney Allograft Dysfunction.Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and/or film-coated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease.Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.Case-matched comparison of ABO-incompatible and ABO-compatible living donor liver transplantation.Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.Incidence of Ganciclovir Resistance in CMV-positive Renal Transplant Recipients and its Association with UL97 Gene Mutations.Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: single center experience.Cytomegalovirus antiviral resistance: characterization of results from clinical specimens.Transient residence of a seropositive organ is sufficient to transfer human cytomegalovirus to a seronegative recipient.
P2860
Q26773183-8B6EE402-8B1C-4D5E-914A-5C471D08C37EQ26863724-13A498E3-6344-4929-AB43-06F0D384C60CQ27026499-993E9696-F0F8-444E-9DDF-9381CFE9F3DAQ35089829-647C7CDF-84AB-4F45-AED8-4A75FE97209CQ36124353-3B90F74D-D4E1-41B4-8C4F-3DE428B39D00Q36369230-54D6AA4B-32D9-491D-9A26-764D8DBE0D7FQ36389162-7BA712F6-DDE7-40DE-8C90-D0D435BABA19Q36669753-CE1C34E8-77B5-4BD1-8787-C90A531F7042Q36691408-12A00D13-EFA0-47C1-8C3C-2F385C141910Q37036219-BF835C6A-5B64-4663-A2EA-21528D3D9B7BQ37137761-FFED8C1B-3089-4F34-BA84-2D7A75F94C67Q37359332-7C41E636-FFE8-4288-AC52-B9D54A09C5D5Q37652611-9980BB34-BA0D-4EF1-87E7-3AA2D28A5BAFQ38097119-04056CD1-FCE6-40FC-B632-3E9200C1746AQ38166861-D77EC2EA-26E2-49B3-8EAF-DB0DBD4CF7E1Q38176940-B6D27201-2D27-4495-969B-4CDDD835DD40Q38187175-CCA75074-7283-4DB7-A650-B2AEB717C94DQ38281851-E0AFEB11-4C7D-4E2A-9B3E-439DBF2105B4Q38370342-2C01FBEB-240C-45D4-81D9-9C622B1699EBQ38417056-F7F5FF01-71E4-42A5-9654-72319F45768CQ38453650-70C61AB8-3371-47D7-A3BB-1D5CA9116911Q38622013-DD42BE71-566B-4C14-A54A-572D752AED81Q38689820-135A6A23-328F-491C-B857-00051039F40DQ38796141-5EC69D26-5982-4B20-8D8A-3F197C58EBC8Q38898723-3E8164B3-DE7A-4493-8937-B1B7CAA52B1EQ38960187-71C9A6F0-8CE0-44B2-8AB0-E9491A49DED1Q40068430-EDDCCE7E-A170-42F1-BB4C-3BD1E5484D97Q40083217-8426BEB2-A1B2-493F-B46A-BE44323A342DQ40140598-4F2CAA37-B6D3-4E37-9646-D18E5013954CQ40278985-46A22360-2C9F-4C5C-A442-95A3D6C85C87Q40483831-CC72E1BD-5C72-42DC-A756-C6D21175E351Q40501883-34C0D3B4-870B-45CD-9467-270C44ECE870Q40537018-4A919C75-5A06-4C1B-B6E3-F72EEDAFCA37Q40860739-344EB679-CF7F-41D5-88A9-BAC4DC7F2BB9Q41138845-8D757522-2266-4279-B584-1F33117C8445Q41218897-9A2ABDB8-2C06-4A82-9B7D-20537DEC5AF7Q41923977-1AE83780-BAA9-4921-9F71-1FB285931C6AQ41994954-B52B841B-D3E9-4954-B3CC-11793D074D77Q42214155-809F6431-7196-40F1-A790-D1117EF85466Q42229229-E24FDEEA-ED34-459D-AA36-575D0B7FDF9B
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
CMV: Prevention, Diagnosis and Therapy
@ast
CMV: Prevention, Diagnosis and Therapy
@en
CMV: Prevention, Diagnosis and Therapy
@nl
type
label
CMV: Prevention, Diagnosis and Therapy
@ast
CMV: Prevention, Diagnosis and Therapy
@en
CMV: Prevention, Diagnosis and Therapy
@nl
prefLabel
CMV: Prevention, Diagnosis and Therapy
@ast
CMV: Prevention, Diagnosis and Therapy
@en
CMV: Prevention, Diagnosis and Therapy
@nl
P2860
P3181
P356
P1476
CMV: Prevention, Diagnosis and Therapy
@en
P2093
C. N. Kotton
P2860
P304
24-40; quiz 40
P3181
P356
10.1111/AJT.12006
P407
P478
13 Suppl 3
P577
2013-02-01T00:00:00Z